2017
Single Dose Of Bisphosphonate To Treat Infantile Hypercalcemia
Patel N, Carpenter T, Genel M. Single Dose Of Bisphosphonate To Treat Infantile Hypercalcemia. AACE Clinical Case Reports 2017, 3: e246-e250. DOI: 10.4158/ep161536.cr.Peer-Reviewed Original ResearchSubcutaneous fat necrosisSingle doseSevere hypercalcemiaDihydroxyvitamin DParathyroid hormonePTH parathyroid hormoneLife-threatening complicationsTreatment of hypercalcemiaLow calcium dietWeeks of lifePosterior upper armPg/mLAggressive hydrationTerm neonatesCalcium dietConfluent plaquesRadiologic findingsFat necrosisTreatment courseTherapeutic coolingSubsequent hypercalcemiaHypercalcemiaInfantile hypercalcemiaCalcium levelsPg/
2014
Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia
Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, Kawakami T, Ito T, Zhang X, Humphrey J, Insogna KL, Peacock M. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. Journal Of Clinical Investigation 2014, 124: 1587-1597. PMID: 24569459, PMCID: PMC3973088, DOI: 10.1172/jci72829.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCalciumFamilial Hypophosphatemic RicketsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGlomerular Filtration RateHalf-LifeHumansInjections, IntravenousInjections, SubcutaneousKidney TubulesMaleMiddle AgedPhosphatesVitamin DYoung AdultConceptsTmP/GFRSerum PiParathyroid hormonePhosphate reabsorptionXLH patientsRenal tubular thresholdSerum parathyroid hormoneFavorable safety profileElevated serum FGF23Renal phosphate reabsorptionLow serum concentrationsPhosphate-regulating endopeptidaseSerum Pi concentrationFGF23 antibodySerum FGF23Dihydroxyvitamin DSafety profileTubular thresholdSingle doseSerum concentrationsKRN23Mean t1/2Potential treatmentPatientsEffect duration
1996
Osteocalcin abnormalities in Hyp mice reflect altered genetic expression and are not due to altered clearance, affinity for mineral, or ambient phosphorus levels
Carpenter T, Gundberg C. Osteocalcin abnormalities in Hyp mice reflect altered genetic expression and are not due to altered clearance, affinity for mineral, or ambient phosphorus levels. Endocrinology 1996, 137: 5213-5219. DOI: 10.1210/en.137.12.5213.Peer-Reviewed Original ResearchDoses of 1,25-(OH)2D3Hyp miceCirculating osteocalcinNormal animalsIncreased serum osteocalcin levelsOsteocalcin mRNAResponse to 1,25-dihydroxyvitamin D3Response to 1,25-(OH)2D3Serum osteocalcin levelsC57 BL/6 miceDietary phosphorus deprivationRenal wastingOsteocalcin levelsDaily doseSingle doseBL/6 miceCirculating levelsParadoxical decreaseAffinity of osteocalcinU-calciumBone osteocalcinMiceOsteocalcinOsteocalcin productionClearance